Home
Solutions
Products
Pricing
Resources
Request Demo
Start Free
Menu Search Account

LegiStorm

Get LegiStorm App Visit Product Demo Website
» Get LegiStorm App
» Get LegiStorm Pro Free Demo
StateStorm

Weekly Updates

LegiStorm is constantly adding new information on the people, places and reports in our database. In the past week, LegiStorm added:

  • 376 new people
  • 171 new organizations
  • 408 new photos
  • 1234 job history records for people in our database
  • 653 education records for people in our database
  • 1467 contact addresses, emails and URLs (LinkedIn, Facebook, etc.)
  • 3 new people through the revolving door
  • 109 new policy reports
  • 43 new trips to our privately funded travel database
  • 629 new personal financial disclosures
  • 15148 new press releases
  • 11 new town halls
  • 25 new hearings

Caught Our Eye Rss

» More from Caught Our Eye
» More from our DevBlog

Anthrax Vaccine: Changes to the Manufacturing Process

  Premium   Download PDF Now (11 pages)
Report Type Reports and Testimonies
Report Date Oct. 23, 2001
Report No. GAO-02-181T
Subject
Summary:

The original anthrax vaccine was developed in the 1950s and was first produced on a large scale by Merck. The BioPort Corporation in Michigan is now the sole facility in the United States capable of producing the vaccine. The Food and Drug Administration (FDA) licenses biological products and their production facilities. The manufacturer is required to comply with current good manufacturing practices, which regulate personnel, buildings, equipment, production controls, records, and other aspects of the vaccine manufacturing process. When there is a major change in the manufacturing process, the manufacturer must submit evidence to FDA showing that the change does not have any adverse effects. The manufacturer must also ensure that the quality of the product is maintained. In the case of the anthrax vaccine, the Michigan facility did not notify FDA of several changes to the manufacturing process in the early 1990s, and no specific studies were done to confirm that vaccine quality was not affected. FDA inspections found several deficiencies, many of which were not corrected in a timely manner.

« Return to search Government Accountability Office reports

HomeAbout Us Contact UsPrivacy PolicyTerms of UseJoin Us
© LegiStorm
LegiStorm
2101 L St. NW, Suite 300
Washington, DC 20037
(202) 360-4172 / congress@legistorm.com